Mergers & Acquisitions

Hospira acquisition of Mayne Pharma clears U.S. antitrust review

Published in Hospital Law Weekly, February 22nd, 2007

Hospira, Inc., (HSP), a global hospital products company, and Mayne Pharma, Ltd., (MYP), an Australia-based specialty-injectable pharmaceuticals company, announced that, subject to the divestiture of certain overlapping products, the U.S. Federal Trade Commission (FTC) has cleared the way for Hospira to proceed with its proposed acquisition of Mayne.

The product divestitures are not material to the transaction.

"We're pleased to receive FTC clearance and move closer to becoming the world's leader in generic injectable pharmaceuticals," said Christopher B. Begley, chief executive officer, Hospira. "Following the combination of our companies, we will...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hospital Law Weekly

Source: Hospital Law Weekly (2007-02-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry